SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
IDMC is on the move buy the open
IDMC
|
|
|
It's looking some strength with IDMC Indy MAc has a bilout plan of it's own and it has already helped 1200 borrowers in the first month. It's worth the high risk trade for a quarter or so. I know it's over the counter but, maybe not for long. Good luck.
|
Bullish on IDMC ...
IDMC
|
|
|
Analysts' Recommendation: Sell 30 Days Ago: Hold ndyMac Bancorp, Inc. operates as the holding company for IndyMac Bank, F.S.B., a thrift/mortgage bank that provides mortgage products and services in the United States. It operates in two segments, Mortgage Banking and Thrift. The Mortgage Banking segment offers adjustable-rate mortgages (ARMs), intermediate term fixed-rate loans, pay option ARMs, fixed-rate mortgages, conforming and non conforming loans, construction-to-permanent loans, subprime mortgages, home equity lines of credits, and reverse mortgages. This segment also ori...
|
Highly notable insider move...
IDMC
|
|
|
People are selling like crazy in fear. Oh my iPod, the sky is falling! And funny enough, I'm the guy who loves saying it the most. :) Well, in a moment of brightening clarity, I came across a news brief on an insider move. IndyMac Bancorp Inc. (NYSE: IMB ) Chairman/CEO, Michael W. Perry, bought 328,988 shares on 2/15 at $7.93, bringing his stake to 578,573 shares. <> If Countrywide's Chairmain Mozilo was selling shares like crazy just when he knew the company was gonna dip like a cripple, what does that say about CEO Perry buying shares increasing his stake by 1<>...
|
financial-types can't admit they are in a bubble worse than the tech bubble of 2000
IDMC
|
|
|
This is the most overvalued stock on the market, the company will be lucky to escape bankruptcy. CFC's mgt was twice as smart about the credit crises than IMB mgt, and CFC mgt was happy to sell themselves in mid single digits (a HUGE decline from highs). Meanwhile, IMB mgt has chosen to try to sweep the credit crunch under the rug, refusing to eliminate the dividend while paying top interest rates on deposits (makes zero sense). <> IMB balance sheet is worth zero, if it's not worth a negative amount (more likely). Even financial-types seem to accept this, but are betting on CFC a<><><><><>...
|
From the Blogosphere
Cell Genesys, Inc. (CEGE) Halts Cancer Treatment Trial to Ensure Patient Safety
|
|
|
Cell Genesys, Inc. (Nasdaq: CEGE) focuses on the development and commercialization of biological therapies to treat multiple types of cancer. The company’s lead product platform, GVAX immunotherapy, holds the potential to treat various types of cancer, including prostate cancer, leukemia, pancreatic cancer and lung cancer. Cell Genesys today announced it has terminated VITAL-2, the second of two phase III clinical trials of GVAX. <>The trial was set to compare GVAX immunotherapy in combination with Taxotere to Taxotere combined with prednisone in patients with advanced-stage prostate c...
|
Cell Genesys, Inc. (CEGE) Halts Cancer Treatment Trial to Ensure Patient Safety
|
|
|
Cell Genesys, Inc. (Nasdaq: CEGE) focuses on the development and commercialization of biological therapies to treat multiple types of cancer. The company’s lead product platform, GVAX immunotherapy, holds the potential to treat various types of cancer, including prostate cancer, leukemia, pancreatic cancer and lung cancer. Cell Genesys today announced it has terminated VITAL-2, the second of two phase III clinical trials of GVAX. <>The trial was set to compare GVAX immunotherapy in combination with Taxotere to Taxotere combined with prednisone in patients with advanced-stage prostate c...
|
Pre-Open Movers 8/27: SI International (SINT) Up on Buyout; Solarfun (SOLF) Falls After Results
|
<>StreetInsider.com Pre-Open Movers:
Cell Genesys, Inc. (Nasdaq: CEGE) 75% LOWER; terminated VITAL-2, the second of two Phase 3 clinical trials of GVAX immunotherapy for prostate cancer, which compares GVAX immunotherapy in combination with Taxotere(R) (docetaxel) to Taxotere plus prednisone in patients with advanced-stage prostate cancer. The Company ended the trial as recommended by its Independent Data Monitoring Committee (IDMC) which, in a routine safety review meeting held this week, observed an imbalance in deaths between the two treatment arms of the study.
NexMed, Inc. (Nasdaq: NEXM)...
|
Option Update: Dendreon and Savient Pharma volatility elevated
Filed under: Options  Dendreon (NASDAQ: DNDN) expects the Independent Data Monitoring Committee (IDMC) to review in October 2008 the interim analysis of overall survival relating to the Company's Phase 3 IMPACT (Immunotherapy for Prostate AdenoCarcinoma Treatment). DNDN November call option implied volatility is at 164, puts are at 195; above its 26-week average of 129 according to Track Data, suggesting larger price fluctuations.
<>Savient Pharma (NASDAQ: SVNT) closed at $21.95 Thursday. SVNT's Puricase (treatment for refractory gout) BLA (biologics license application) filing is expected this ...
|
Although Federal Reserve Policymakers Are Set to Meet, They Have Little Room to Maneuver
|
|
|
By William Patalon III
Executive Editor
Money Morning/The Money Map ReportU.S. Federal Reserve Chairman Ben S. Bernanke and his fellow central bank policymakers will be back in the spotlight this week as the group convenes for its monthly monetary-policy meeting.But there won’t be much to report.Although the Federal Reserve’s policymaking Federal Open Market Committee (FOMC) meets Wednesday, the group doesn’t have much room to maneuver: If the Fed cuts rates to stimulate growth, already troublesome inflation could escalate out of control. But if the FOMC raises rates to reign in<><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>< /><><><>< /><><>< /><>< /><>< />< />...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on IDMC |
Visit streetinsider.com
Be the first to start a discussion and earn 2 points.
More Resources
|
About INDYMAC BANCORP INC
- Answers.com
